Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)
Part of paid clinical trials in Aventura, California.
- Sponsor
- Rigel Pharmaceuticals
- Study ID
- NCT00665626
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Fostamatinib disodium (R935788) — DRUGR935788 100 mg tablet, orally, twice-a-day
- Placebo — DRUGPlacebo, orally, twice-a-day
Study Details
The purpose of this study is to determine whether the Spleen Tyrosine Kinase (Syk) Inhibitor, R935788 (R788) at a dose of 100 mg, tablet, orally, twice-a-day is effective in the treatment of Rheumatoid Arthritis in patients who have 'failed' a biologic therapy.
Key Dates
- Start date
- May 31, 2008
- Status verified
- Mar 2017
- Primary completion
- Jun 30, 2009
- Completion
- Jun 30, 2009
Study Design
- Enrollment
- 219 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm 1Fostamatinib disodium (R935788) 100 mg tablet, orally, twice-a-day
- Placebo Comparator: Arm 2Placebo, orally, twice-a-day
Primary Outcome Measure
American College of Rheumatology 20 (ACR20) Response at 3 Months [ Time Frame: 3 months ]
Locations (27)
Find similar trials in Aventura, CA
By condition
By research site
Related Studies
- Physica System Total Knee Replacement Registry StudyRecruiting · Limacorporate S.p.a · Rancho Mirage, California
- Early Rheumatoid Arthritis Lung Disease StudyRecruiting · University of Nebraska · Omaha, Nebraska
- Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponsePHASE3 · Recruiting · University of Nebraska · Omaha, Nebraska
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama